peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

bacteriocin peptide

Nisin

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

Nisin is classified as an antimicrobial peptide (a peptide with antimicrobial activity).

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Nisin is described as an antimicrobial peptide with a net positive (cationic) charge.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Nisin, a cationic antimicrobial peptide, has been reported for its cytotoxicity against some cancer cell lines via several mechanisms, particularly membrane disruption.

    Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability. · Abstract

    pubmed:42335141:30f664226535:30f664226535

Identity

The term lantibiotic refers to antimicrobial peptides that contain lanthionine.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    lantibiotics, so called because they contain the unusual amino acid lanthionine.

    Nisin as a model food preservative. · Abstract

    pubmed:8142045:2c35c8508fcf:2c35c8508fcf

Identity

Nisin is produced via ribosomal synthesis (i.e., made by transcription/translation rather than nonribosomal assembly).

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Nisin is a ribosomally synthesized peptide

    Nisin as a model food preservative. · Abstract

    pubmed:8142045:2c35c8508fcf:2c35c8508fcf

Identity

Nisin is classified as a class I bacteriocin, i.e., a lantibiotic antimicrobial peptide.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Nisin, a member of class I bacteriocins known as lantibiotics,

    Nisin-A lantibiotic with immunomodulatory properties: A review. · Abstract

    pubmed:33359393:8bf703f8a20d:8bf703f8a20d

Identity

The peptide nisin is biosynthesized by the lactic acid bacterium Lactococcus lactis.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    is produced by the lactic acid bacterium Lactococcus lactis

    Nisin-A lantibiotic with immunomodulatory properties: A review. · Abstract

    pubmed:33359393:8bf703f8a20d:8bf703f8a20d

Identity

Nisin is a bacterially produced antimicrobial peptide, specifically produced by Lactococcus lactis.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    This systematic review synthesizes current knowledge on nisin, an antimicrobial peptide produced by Lactococcus lactis , and explores its expanding applications across multiple fields.

    Nisin: harnessing nature's preservative for the future of food safety and beyond. · Abstract

    doi:10.1080/10408398.2025.2517822:5a61bf940890:5a61bf940890

Identity

Nisin is described as a peptide antibiotic that is post-translationally modified.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    The post-translationally modified peptide antibiotic nisin

    Structure-activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin. · Abstract

    pubmed:8706842:f319176b0f22:f319176b0f22

Identity

In this study, nisin was formulated as part of soluble soybean polysaccharide–nisin nanoparticles (PS-NPs) incorporated into a poly(vinyl alcohol)/soy protein isolate pad, with the nanoparticles loaded with oregano essential oil.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Here, we coupled longitudinal 16S rRNA gene profiling with conventional microbiological and quality measurements to evaluate a poly(vinyl alcohol)/soy protein isolate pad containing OEO-loaded soluble soybean polysaccharide-nisin nanoparticles (PS-NPs).

    Effects of a Nanoparticle-Loaded PVA/SPI Pad on Microbial Proliferation and Quality Characteristics of Superchilled Pork. · Abstract

    pubmed:42650524:6093c44dbbb4:6093c44dbbb4

Identity

Nisin is reported to have a molecular weight of 3353.11.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Molecular weight: 3353.11

    NISIN · Molecular properties

    chembl-molecule:chembl526744:947db98f3669:947db98f3669

Identity

Nisin is classified as a bacteriocin and is commonly used for food biopreservation.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Bacteriocin-phage interactions (BaPIs) were determined in vitro for nisin, a bacteriocin commonly used as a food biopreservative.

    Bacteriocin presence enhances phage-related risks in dairy fermentations. · Abstract

    pubmed:42083187:d8f801baa9d9:d8f801baa9d9

Identity

Within the antimicrobial peptide literature, nisin A and related variants are described as extensively studied.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Nisin A and its variants are among the most extensively studied antimicrobial peptides.

    The role of the antimicrobial peptide nisin as a clean label food preservative. · Abstract

    pubmed:42378947:d485a2129c26:d485a2129c26

Identity

The molecular composition of nisin is given by the formula C142H227N43O37S7.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Molecular formula: C142H227N43O37S7

    NISIN · Molecular properties

    chembl-molecule:chembl526744:947db98f3669:947db98f3669

Identity

Nisin is classified as an antimicrobial peptide (a peptide with antimicrobial activity).

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Nisin is an antimicrobial peptide

    Promotion of nisin production by integrating rare earth salt stimulation and foam separation with fermentation system. · Abstract

    pubmed:42592668:683cbeed102b:683cbeed102b

Identity

Nisin is classified as a bacteriocin (a bacterially produced antimicrobial peptide).

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    The bacteriocin nisin can play a role in addressing the global need for safe, effective, and 'clean label' preservation strategies.

    The role of the antimicrobial peptide nisin as a clean label food preservative. · Abstract

    pubmed:42378947:d485a2129c26:d485a2129c26

How does it work?

Target, response, and disposition.

Mechanism

Structure-activity optimization of nisin variants is described as targeting improved physicochemical characteristics.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    We highlight recent advances aimed at overcoming these challenges, including novel delivery systems and the development of novel nisin variants with improved physicochemical properties, resistance to enzymatic degradation, and expanded antimicrobial spectra.

    The role of the antimicrobial peptide nisin as a clean label food preservative. · Abstract

    pubmed:42378947:d485a2129c26:d485a2129c26

Mechanism

In this work, tFNAs function as a nucleic-acid nanoplatform for co-delivery of the antimicrobial peptide nisin with quercetin to an MRSA isolate.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Here, tetrahedral framework nucleic acids (tFNAs) were engineered as a nanoplatform to co-deliver nisin and quercetin (tFNQ) against a methicillin-resistantStaphylococcus aureus(MRSA) strain isolated from retail pork.

    A tetrahedral framework nucleic acid-based co-delivery platform enhances the antibacterial activity of nisin and quercetin against MRSA. · Abstract

    pubmed:42671339:464d6ee5ad92:464d6ee5ad92

Mechanism

Under sublethal free nisin exposure, the S. aureus proteome showed increased levels of proteins mapping to core functions (translation and ribosomes), metabolic pathways, transport (ABC systems), membrane-associated processes, and stress/redox responses—consistent with an adaptive response signature.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Proteins upregulated by free nisin treatment were related to the modulation of ribosomal function, protein translation, energy metabolism, ATP-binding cassette (ABC) transport systems, membrane-associated proteins, cellular stress and redox homeostasis.

    Proteomic response of Staphylococcus aureus exposed to nisin and liposome-encapsulated nisin. · Abstract

    pubmed:42177953:9aa1891e9b20:9aa1891e9b20

Mechanism

Proteomics indicated that sublethal free nisin exposure coincided with reduced levels of S. aureus proteins annotated for host-interaction and adhesion functions.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    At the same time, the downregulated proteins were associated with host-interaction and adhesion.

    Proteomic response of Staphylococcus aureus exposed to nisin and liposome-encapsulated nisin. · Abstract

    pubmed:42177953:9aa1891e9b20:9aa1891e9b20

Mechanism

A nisin-inducible expression system (pNZ8149) was used to drive recombinant expression of codon-optimized NGPV VP3 or a VP3-IFNα fusion in Lactococcus lactis NZ3900.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Codon-optimized genes encoding NGPV VP3 and a VP3-IFNα fusion were cloned into the nisin-inducible pNZ8149 vector and expressed in L. lactis NZ3900.

    Oral immunization with recombinant Lactococcus lactis expressing VP3 and VP3-IFNα fusion protein protects ducklings against novel goose parvovirus infection. · Abstract

    pubmed:41933533:60f509b579d8:60f509b579d8

Mechanism

The peptide is reported to preferentially associate with anionic phospholipids, leading to membrane pore formation.

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Nisin can bind preferentially to the negatively charged phospholipids, causing pore formation in cell membranes.

    Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability. · Abstract

    pubmed:42335141:30f664226535:30f664226535

What has been studied?

What the evidence says.

Comparative evidence

Using the PolyFermS continuous fermentation system to simulate chicken caecal conditions, investigators compared nisin Z with a positive-control antibiotic (bacitracin) to assess changes in microbiota composition and metabolic activity.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    This study compared the impact of three bacteriocins-microcin J25, nisin Z, and pediocin PA-1-against bacitracin as a positive control, specifically evaluating their effects on gut microbiota composition and metabolic activity. The study utilized the PolyFermS continuous fermentation model to simulate chicken caecal conditions.

    Uncovering how selected potent bacteriocins reshape the broiler chicken gut microbiome in a PolyFermS continuous in vitro model. · BACKGROUND

    pubmed:42277887:df0ec0e640c5:df0ec0e640c5

Study findings

In a mouse model, intraperitoneal nisin F (640 arbitrary units in 200 μl) was associated with stability of the gastro-intestinal tract bacterial community composition over 48 h relative to saline, based on 16S rDNA PCR-DGGE profiles from fecal samples.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Six male C57BL/6 mice were intraperitoneally injected with 200 μl sterile saline and six with nisin F (200 μl, equivalent to 640 arbitrary units). Fecal samples were collected before injection and 8, 24 and 48 h after injection, and the bacteria amplified by PCR-DGGE using 16S rDNA primers. The composition of the bacterial population in the gastro-intestinal tract (GIT) of mice that were injected with saline changed during 48 h, whereas the bacterial population in the GIT remained relatively unchanged in animals injected with nisin F.

    Nisin F, intraperitoneally injected, may have a stabilizing effect on the bacterial population in the gastro-intestinal tract, as determined in a preliminary study with mice as model. · METHODS AND RESULTS

    pubmed:21609345:7db43f711ba2:7db43f711ba2

Study findings

In an in vitro bacteriophage assay, nisin increased plaque size for lactococcal phages P2 and bIL170, indicating altered plaque morphology under these conditions.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Nisin increased the plaque size for the lactococcal phages P2 and bIL170.

    Bacteriocin presence enhances phage-related risks in dairy fermentations. · Abstract

    pubmed:42083187:d8f801baa9d9:d8f801baa9d9

Study findings

In an in vitro inhibition-zone assay versus S. aureus and E. coli, nisin inclusion conferred measurable antibacterial activity to CS-PVA scaffolds.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    CS-PVA scaffolds showed no inhibition, whereas CS-PVA-nisin exhibited significant antibacterial activity with inhibition zones of 34.5 mm for S. aureus and 25.4 mm for E. coli.

    Fabrication and investigation of chitosan/PVA and chitosan/PVA/nisin nanofibers via electrospinning as potential wound dressing agents. · Abstract

    pubmed:42466784:e8373cd6d7a0:e8373cd6d7a0

Study findings

Short-chain fatty acid profiling indicated that nisin Z caused a statistically significant, time-dependent reduction in butyrate, reaching its greatest reduction at 48 h post-injection.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Short-chain fatty acid analysis revealed a significant time-dependent decrease in butyrate levels following nisin Z and bacitracin treatments, with the most pronounced reduction observed at 48 h post-injection.

    Uncovering how selected potent bacteriocins reshape the broiler chicken gut microbiome in a PolyFermS continuous in vitro model. · RESULTS

    pubmed:42277887:df0ec0e640c5:df0ec0e640c5

Study findings

In the in vitro assessment for bIL170, nisin affected plaque size but did not measurably change burst size or latent period.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    However, bIL170 burst size and latent period remained unaltered.

    Bacteriocin presence enhances phage-related risks in dairy fermentations. · Abstract

    pubmed:42083187:d8f801baa9d9:d8f801baa9d9

Study findings

Stability assay results indicated that nisin Z had rapid loss of antimicrobial activity under the tested conditions.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Stability assays confirmed that microcin J25 remained active up to 24 h, whereas nisin Z and pediocin PA-1 lost antimicrobial activity rapidly.

    Uncovering how selected potent bacteriocins reshape the broiler chicken gut microbiome in a PolyFermS continuous in vitro model. · RESULTS

    pubmed:42277887:df0ec0e640c5:df0ec0e640c5

Study findings

Based on 16S rRNA sequencing, nisin Z exposure was associated with a significant shift in community composition, including reductions in Lactobacillaceae and Ruminococcaceae.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    16S rRNA sequencing revealed that bacitracin and nisin Z significantly altered the microbiota composition, reducing key families such as Lactobacillaceae and Ruminococcaceae

    Uncovering how selected potent bacteriocins reshape the broiler chicken gut microbiome in a PolyFermS continuous in vitro model. · RESULTS

    pubmed:42277887:df0ec0e640c5:df0ec0e640c5

Study findings

In vitro experiments evaluated nisin across 14–450 µg/mL to assess its impact on Listeria monocytogenes growth kinetics and biofilm formation in two strains.

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    The effects of nisin on growth inhibition and biofilm formation were studied in twoListeria monocytogenesstrains, LM_ATCC 19115 and LM_18, at concentrations ranging from 14 to 450 µg/mL.

    Impact of Nisin on Growth Inhibition and Biofilm Formation Capacity ofListeria monocytogenes. · Abstract

    pubmed:42653358:f037fcdafc70:f037fcdafc70

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Additional research & classification gaps

58 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.

Inspect contextual research (58)
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Compared with reduced-salt frankfurters using commercially available preservatives, the study reported a 4.08% longer shelf life when nisin was included in the ternary preservative system (per a predictive model).

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Relative to preservative-free reduced-salt frankfurters, the study reported a 54.55% greater shelf life when nisin was included as part of the ternary preservative system (as assessed by a predictive model).

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

When nisin was delivered in liposomes (lipo-nisin), the observed S. aureus proteome resembled the control condition in this study’s proteomic profiling.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The abstract reports that environmental variables (surface material, biofilm age, hydrodynamic conditions) are highlighted as determinants of biofilm architecture and susceptibility to antimicrobials.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The abstract states bacteriocins are being explored for roles including antibiotic alternatives, microbiota modulation, and bacterial signaling.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin-variant development is described as aiming to broaden antimicrobial spectrum beyond existing limitations.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

When nisin was used as part of a ternary biological preservative, bacterial community diversity in the product was reported to decrease significantly under refrigerated storage conditions.

Research context only—not evidence of a treatment effect.

Analytical / formulation research

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Untargeted LC-MS metabolomics suggested that nisin Z substantially changed the metabolic profile, with increases reported in amino acids and cyclic dipeptide levels.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin exposure decreased biofilm formation; at 450 µg/mL, LM_ATCC 19115 showed complete absence of observable biofilm under the study conditions.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In C. perfringens spores, the combined treatment of tea polyphenols and nisin (TPN) decreased spore viability by 22.1%.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Food-matrix complexity can limit nisin performance via reduced solubility when pH is neutral.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In refrigerated reduced-salt frankfurters, adding a nisin-containing ternary preservative was associated with lower relative abundance of the spoilage bacterium Brochothrix thermosphacta versus control at day 70.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In the described fungal production system, adding a nisin Z-producing Lactococcus lactis co-culture did not change EGT production relative to the fungal producer strain alone (reported as equivalent).

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Within the study’s analyzed relationships between taxa and quality metrics, Pseudomonas psychrophila was most strongly positively associated with protein carbonyl content compared with other evaluated taxon-quality pairs.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Based on the study’s observed microbial-community and quality-measure changes during superchilled storage, the authors conclude PS-NPs are supported as a preservation strategy.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In a soft white cheese food model, nisin combined with EDTA reduced growth across single-culture and poly-microbial culture conditions.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Engineering nisin variants to resist enzymatic degradation is highlighted as a way to address limitations such as proteolysis.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin is described as having a wide antibacterial spectrum targeting gram-positive bacteria.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In this study, the PS-NPs condition was associated with lower cooking loss compared with the no-pad control (CK), based on the reported percentages.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Structural analyses indicated that combined tea polyphenols and nisin (TPN) produced pronounced surface wrinkling and altered the conformation of spore surface proteins in C. perfringens spores.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

When tested in reconstituted orange juice, the combination’s sporicidal potency against A. acidoterrestris spores was quantified as an MSC of 0.48 µg/mL.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin is described as having worldwide success in use as a natural food preservative.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Relative to the no-pad control (CK), the PS-NPs packaging condition was associated with slower microbial proliferation (viable counts) and delayed physicochemical and sensory deterioration under superchilling.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The PEGylated niosome co-delivery system containing nisin and ZnO nanoparticles demonstrated favorable formulation performance metrics: high encapsulation efficiency, sustained-release kinetics, and good physicochemical stability.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In this source, fermentation-associated lactic acid accumulation is described as causing self-induced acid stress, which can constrain production of products including the peptide nisin.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Under refrigerated storage (4 °C), the presence of nisin within the ternary biological preservative was reported to improve retention of moisture and color attributes in the product.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Checkerboard testing in culture medium found synergy between D-limonene and nisin against A. acidoterrestris, quantified by an FICI of 0.07.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

At a concentration of 2.4 mg/mL, the combined tea polyphenols and nisin treatment significantly slowed the kinetics of C. perfringens spore germination.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin incorporation increased the water contact angle, consistent with reduced surface hydrophilicity compared with CS-PVA.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Using a predictive model, the study reported that adding nisin as part of the ternary biological preservative corresponded to a confirmed shelf life of 102-day for the product.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin incorporation altered nanofiber morphology, increasing mean fiber diameter and reducing scaffold porosity as measured by scanning electron microscopy.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

At day 24 of storage, the relative abundance of Pseudomonas differed between conditions, being lower with PS-NPs than in the no-pad control (CK).

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In silico mining of Hungate1000 genomes found hundreds of previously unreported bacteriocin biosynthetic gene clusters across many genomes.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The review identifies a knowledge gap regarding strategies to mitigate bacterial resistance to nisin effectively.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Under PS-NPs packaging, lipid oxidation (TBARS) and protein oxidation (protein carbonyls) measures were reduced relative to the no-pad control (CK) by the stated percentages.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Subtilin is described as a naturally occurring structural analog of nisin.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

A key-point summary states that the CAB701 and WiKim0124 strains uniquely harbor biosynthetic clusters for nisin Z.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin is identified in this study context as a commercially used food preservative (used as a comparator in a simulated milk model).

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Comparative genomics identified nisin Z biosynthetic gene clusters that are unique to the L. lactis subsp. lactis strains CAB701 and WiKim0124.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

ChEMBL classifies nisin (CHEMBL526744) under the molecule type “Small molecule.”

Research context only—not evidence of a treatment effect.

  • NISIN
    Molecule type: Small molecule
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin belongs to the lantibiotics, a class of antimicrobial substances.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The abstract identifies L. lactis F44 as producing nisin, indicating it is a microbial producer used in this study context.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin Z (a bacteriocin variant) is attributed in the abstract to production by Lactococcus lactis JCM 7638 used for co-culture.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin is indexed in ChEMBL under the identifier CHEMBL526744.

Research context only—not evidence of a treatment effect.

  • NISIN
    ChEMBL ID: CHEMBL526744
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In ChEMBL nomenclature, CHEMBL526744’s preferred name is NISIN.

Research context only—not evidence of a treatment effect.

  • NISIN
    Preferred name: NISIN
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Bacteriocins are antimicrobial peptides/proteins produced by bacteria and are broadly distributed across bacterial taxa.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Gene-encoded lantibiotic peptides are produced via transcription/translation, which enables generation of structural variants through mutagenesis of the encoding genes.

Research context only—not evidence of a treatment effect.

  • Nisin as a model food preservative.
    The fact that lantibiotics are gene-encoded peptides synthesized by transcription and translation allows structural variants to be generated by mutagenesis.
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Nisin was included as a reference antibiotic with a previously established mechanism of action for method evaluation.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Spectroscopic (FTIR) evidence supported nisin incorporation into the scaffold, identified by peaks at 3330 cm-1 and 2918 cm-1.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Genome mining (in silico methods) was used on Hungate1000 rumen-isolated prokaryotes to identify bacteriocin biosynthetic potential.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

A research gap noted in the review is incomplete understanding of the mechanisms by which bacteria develop resistance to nisin.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The abstract frames nisin as a natural preservative candidate for controlling microbial growth in foods, considered together with D-limonene.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Proteomic profiling of S. aureus after sublethal free nisin exposure found many proteins changed in abundance (80 increased, 40 decreased), suggesting a distinct metabolic adaptation to sublethal bacteriocin stress.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Mechanistically, combined tea polyphenols and nisin (TPN) disrupted inner membrane integrity in C. perfringens spores, leading to irreversible macromolecule leakage and altered redox homeostasis.

Research context only—not evidence of a treatment effect.

Analytical / formulation research

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

An FTIR-ATR-based analytical method was adapted to detect structural/molecular perturbations in bacteria after antimicrobial exposure; nisin was among the antimicrobials tested.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The abstract reports the use of foam separation as an in-situ method to recover nisin from a fermentation system.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The abstract attributes large-scale production difficulty for nisin to low synthesis efficiency and severe feedback inhibition.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The vraDEH gene set is described as contributing to bacterial resistance mechanisms against nisin (and bacitracin) in clinical Staphylococcus aureus isolates.

Research context only—not evidence of a treatment effect.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
  • 216 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (176), assurance_score_below_0.72 (27), current_regulatory_source_required (25), extraction_ambiguity (178), extraction_confidence_not_high (2), high_risk_requires_regulatory_or_two_independent_sources (38), no_direct_support (201), proposal_not_staged (1)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. NISIN

    chembl-molecule · published 2026-08-28 · retrieved 2026-08-28T12:35:21Z

  2. Nisin: harnessing nature's preservative for the future of food safety and beyond.

    doi · published 2025-06-18 · retrieved 2026-09-09T18:03:03Z

  3. Nisin F, intraperitoneally injected, may have a stabilizing effect on the bacterial population in the gastro-intestinal tract, as determined in a preliminary study with mice as model.

    pubmed · published 2011-08-01 · retrieved 2026-09-09T18:03:03Z

  4. Nisin-A lantibiotic with immunomodulatory properties: A review.

    pubmed · published 2021-03-01 · retrieved 2026-09-09T22:29:05Z

  5. Incorporation of ternary biological preservatives into reduced-salt frankfurters for extended shelf life and enhanced storage quality.

    pubmed · published 2026-07-01 · retrieved 2026-09-05T09:00:33Z

  6. Oral immunization with recombinant Lactococcus lactis expressing VP3 and VP3-IFNα fusion protein protects ducklings against novel goose parvovirus infection.

    pubmed · published 2026-07-01 · retrieved 2026-09-05T09:00:33Z

  7. Bacteriocin presence enhances phage-related risks in dairy fermentations.

    pubmed · published 2026-07-01 · retrieved 2026-09-05T09:00:33Z

  8. Multidimensional synergistic inhibition of Clostridium perfringens spores by nisin and tea polyphenols: a systematic insight from interference germination to metabolic imbalance.

    pubmed · published 2026-07-31 · retrieved 2026-09-05T09:00:33Z

  9. Antimicrobial efficacy and food application potential of bacteriocins LL3 and LL4 from traditional dairy-derived Lactococcus lactis.

    pubmed · published 2026-08-01 · retrieved 2026-09-05T09:00:33Z

  10. An optimized physical-chemical method for analyzing cell perturbations using FTIR-ATR spectrophotometry.

    pubmed · published 2026-08-01 · retrieved 2026-09-05T09:00:33Z

  11. Proteomic response of Staphylococcus aureus exposed to nisin and liposome-encapsulated nisin.

    pubmed · published 2026-08-01 · retrieved 2026-09-05T09:00:33Z

  12. The Hungate1000 prokaryotic culture collection encodes a wide variety of bacteriocins.

    pubmed · published 2026-06-23 · retrieved 2026-09-05T09:00:33Z

  13. Comparative genomics reveals immunomodulatory and anti-obesity traits of Lactococcus lactis subsp. lactis.

    pubmed · published 2026-06-06 · retrieved 2026-09-05T09:00:33Z

  14. Uncovering how selected potent bacteriocins reshape the broiler chicken gut microbiome in a PolyFermS continuous in vitro model.

    pubmed · published 2026-06-12 · retrieved 2026-09-05T09:00:33Z

  15. A subclade-associated genomic deletion encompassing vraDEH confers increased susceptibility to nisin A and bacitracin in Staphylococcus aureus CC121.

    pubmed · published 2026-06-19 · retrieved 2026-09-05T09:00:33Z

  16. Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability.

    pubmed · published 2026-01-01 · retrieved 2026-09-05T09:00:33Z

  17. The role of the antimicrobial peptide nisin as a clean label food preservative.

    pubmed · published 2026-08-01 · retrieved 2026-08-28T12:35:21Z

  18. Metabolic profiling and microbiological evaluation of Staphylococcus aureus in a poly-microbial system in soft white cheese.

    pubmed · published 2026-07-04 · retrieved 2026-09-05T09:00:33Z

  19. A transcription Factor-sRNA cascade enhances acid tolerance in Lactococcus lactis by rewiring arginine metabolism.

    pubmed · published 2026-12-01 · retrieved 2026-08-28T12:35:21Z

  20. Enhanced antibacterial and anti-biofilm activity of PEGylated niosomes co-loaded with nisin and ZnO nanoparticles against VRSA and ceftazidime-resistant Pseudomonas aeruginosa.

    pubmed · published 2026-07-16 · retrieved 2026-09-05T09:00:33Z

  21. Fabrication and investigation of chitosan/PVA and chitosan/PVA/nisin nanofibers via electrospinning as potential wound dressing agents.

    pubmed · published 2026-07-17 · retrieved 2026-09-05T09:00:33Z

  22. Association of D-limonene and nisin: the action on vegetative cells and spores of Alicyclobacillus spp. in processed orange juice.

    pubmed · published 2026-07-24 · retrieved 2026-09-05T09:00:33Z

  23. Promotion of nisin production by integrating rare earth salt stimulation and foam separation with fermentation system.

    pubmed · published 2026-01-01 · retrieved 2026-09-05T09:00:33Z

  24. The "One-Two Punch": A conceptual analysis of nisin and lysozyme synergy against Listeria monocytogenes biofilms and their dependence on environmental factors.

    pubmed · published 2026-08-26 · retrieved 2026-08-28T12:35:21Z

  25. Effects of a Nanoparticle-Loaded PVA/SPI Pad on Microbial Proliferation and Quality Characteristics of Superchilled Pork.

    pubmed · published 2026-08-14 · retrieved 2026-09-05T09:00:33Z

  26. Impact of Nisin on Growth Inhibition and Biofilm Formation Capacity ofListeria monocytogenes.

    pubmed · published 2026-08-17 · retrieved 2026-09-05T09:00:33Z

  27. A tetrahedral framework nucleic acid-based co-delivery platform enhances the antibacterial activity of nisin and quercetin against MRSA.

    pubmed · published 2026-08-31 · retrieved 2026-09-05T09:00:33Z

  28. Bioengineering and physicochemical optimization of ergothioneine production by Aspergillus oryzae.

    pubmed · published 2026-09-04 · retrieved 2026-09-05T09:00:33Z

  29. Nisin as a model food preservative.

    pubmed · published 1994-01-01 · retrieved 2026-09-09T18:03:03Z

  30. Structure-activity relationships in the peptide antibiotic nisin: antibacterial activity of fragments of nisin.

    pubmed · published 1996-07-22 · retrieved 2026-09-09T18:03:02Z

Publication history and provenance

Version 2 · Automated assessment · 2026-09-09T22:29:05Z

c441ff1cad099a9352dc3525865ab7539111a4bc279404c86a031ac0946c4835